United States Biotechnology & Medical Research

Gilead Palo Alto Inc (CVTX)

Track

Ticker: CVTX Exchange: NMQ
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
SPIEGELMAN DANIEL K SVP, CFO Officer
Transaction date
Sale
Price
63.24
Quantity 139 +24.1%
Value US$2,416,253
SPIEGELMAN DANIEL K SVP, CFO Officer
Transaction date
Sale
Price
272.35
Quantity 58,101 -9.2%
Value US$3,223,340
SPIEGELMAN DANIEL K SVP, CFO Officer
Transaction date
Sale
Price
289.92
Quantity 89,471 -40.7%
Value US$918,835
LANGE LOUIS G Chairman & CEO Executive Director
Transaction date
Sale
Price
19.90
Quantity 278,477 -35.6%
Value US$5,541,692
LANGE LOUIS G Chairman & CEO Executive Director
Transaction date
Sale
Price
19.90
Quantity 16,154 -4.0%
Value US$321,465
LANGE LOUIS G Chairman & CEO Executive Director
Transaction date
Sale
Price
19.90
Quantity 45,929 -10.7%
Value US$913,987
LANGE LOUIS G Chairman & CEO Executive Director
Transaction date
Sale
Price
19.90
Quantity 138,615 -26.8%
Value US$2,758,438
STUART LEWIS J SVP COMMERCIAL OPERATIONS Officer
Transaction date
Planned sale
Price
9.23
Quantity 1,002 -7.0%
Value US$9,248
STUART LEWIS J SVP COMMERCIAL OPERATIONS Officer
Transaction date
Sale
Price
8.19
Quantity 2,000 -14.7%
Value US$16,380
BLACKBURN BRENT K SVP, Drug Discovery & Dev Officer
Transaction date
Planned sale
Price
8.93
Quantity 2,000 -6.6%
Value US$17,860
BLACKBURN BRENT K SVP, Drug Discovery & Dev Officer
Transaction date
Planned sale
Price
9.50
Quantity 12,500 -26.8%
Value US$118,750
BLACKBURN BRENT K SVP, Drug Discovery & Dev Officer
Transaction date
Planned sale
Price
9.51
Quantity 12,500 -25.6%
Value US$118,875
BLACKBURN BRENT K SVP, Drug Discovery & Dev Officer
Transaction date
Planned sale
Price
9.50
Quantity 10,000 -22.9%
Value US$95,000
GUTSHALL THOMAS L Non-Executive Director
Transaction date
Sale
Price
9.01
Quantity 7,500 -60.0%
Value US$67,560
BLACKBURN BRENT K SVP, Drug Discovery & Dev Officer
Transaction date
Planned sale
Price
9.63
Quantity 3,951 -11.5%
Value US$38,048
BLACKBURN BRENT K SVP, Drug Discovery & Dev Officer
Transaction date
Planned sale
Price
9.74
Quantity 15,000 -30.4%
Value US$146,100
SPIEGELMAN DANIEL K SVP, CFO Officer
Transaction date
Planned sale
Price
10.03
Quantity 8,000 -46.4%
Value US$80,240
STUART LEWIS J SVP COMMERCIAL OPERATIONS Officer
Transaction date
Planned sale
Price
10.19
Quantity 2,497 -31.7%
Value US$25,444
BLACKBURN BRENT K SVP, Drug Discovery & Dev Officer
Transaction date
Sale
Price
10.09
Quantity 10,000 -30.2%
Value US$100,900
SPIEGELMAN DANIEL K SVP, CFO Officer
Transaction date
Planned sale
Price
13.93
Quantity 7,000 -61.5%
Value US$97,510
MCNEIL BARBARA J Non-Executive Director
Transaction date
Sale
Price
13.60
Quantity 1,800 -41.9%
Value US$24,480
SPIEGELMAN DANIEL K SVP, CFO Officer
Transaction date
Planned sale
Price
12.92
Quantity 3,000 -46.6%
Value US$38,760
MCNEIL BARBARA J Non-Executive Director
Transaction date
Sale
Price
24.53
Quantity 8,000 -76.2%
Value US$196,240
SPIEGELMAN DANIEL K SVP, CFO Officer
Transaction date
Sale
Price
25.21
Quantity 26,500 -100.0%
Value US$668,065
BLACKBURN BRENT K SVP, Drug Discovery & Dev Officer
Transaction date
Sale
Price
25.73
Quantity 8,000 -44.5%
Value US$205,840
SPIEGELMAN DANIEL K SVP, CFO Officer
Transaction date
Sale
Price
26.24
Quantity 21,506 -100.0%
Value US$564,317
SHENK THOMAS E Non-Executive Director
Transaction date
Purchase
Price
20.36
Quantity 1,000 +inf%
Value US$20,360
SPIEGELMAN DANIEL K Senior Vice President and CFO Officer
Transaction date
Planned sale
Price
23.86
Quantity 7,500 -27.3%
Value US$178,954
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2009-04-03 2009-04-02 S Sale SPIEGELMAN DANIEL K

SVP, CFO

Officer
139 +24.1%
63.24
US$2,416,253 		139 +24.1% 63.24 US$2,416,253
2009-04-03 2009-04-02 S Sale SPIEGELMAN DANIEL K

SVP, CFO

Officer
58,101 -9.2%
272.35
US$3,223,340 		58,101 -9.2% 272.35 US$3,223,340
2009-04-03 2009-04-02 S Sale SPIEGELMAN DANIEL K

SVP, CFO

Officer
89,471 -40.7%
289.92
US$918,835 		89,471 -40.7% 289.92 US$918,835
2009-04-03 2009-04-02 S Sale LANGE LOUIS G

Chairman & CEO

Executive Director
278,477 -35.6%
19.90
US$5,541,692 		278,477 -35.6% 19.90 US$5,541,692
2009-04-03 2009-04-02 S Sale LANGE LOUIS G

Chairman & CEO

Executive Director
16,154 -4.0%
19.90
US$321,465 		16,154 -4.0% 19.90 US$321,465
2009-04-03 2009-04-02 S Sale LANGE LOUIS G

Chairman & CEO

Executive Director
45,929 -10.7%
19.90
US$913,987 		45,929 -10.7% 19.90 US$913,987
2009-04-03 2009-04-02 S Sale LANGE LOUIS G

Chairman & CEO

Executive Director
138,615 -26.8%
19.90
US$2,758,438 		138,615 -26.8% 19.90 US$2,758,438
2008-12-10 2008-12-10 PlS Planned sale STUART LEWIS J

SVP COMMERCIAL OPERATIONS

Officer
1,002 -7.0%
9.23
US$9,248 		1,002 -7.0% 9.23 US$9,248
2008-12-10 2008-11-20 S Sale STUART LEWIS J

SVP COMMERCIAL OPERATIONS

Officer
2,000 -14.7%
8.19
US$16,380 		2,000 -14.7% 8.19 US$16,380
2008-10-15 2008-10-14 PlS Planned sale BLACKBURN BRENT K

SVP, Drug Discovery & Dev

Officer
2,000 -6.6%
8.93
US$17,860 		2,000 -6.6% 8.93 US$17,860
2008-08-01 2008-07-31 PlS Planned sale BLACKBURN BRENT K

SVP, Drug Discovery & Dev

Officer
12,500 -26.8%
9.50
US$118,750 		12,500 -26.8% 9.50 US$118,750
2008-04-29 2008-04-25 PlS Planned sale BLACKBURN BRENT K

SVP, Drug Discovery & Dev

Officer
12,500 -25.6%
9.51
US$118,875 		12,500 -25.6% 9.51 US$118,875
2008-01-10 2008-01-10 PlS Planned sale BLACKBURN BRENT K

SVP, Drug Discovery & Dev

Officer
10,000 -22.9%
9.50
US$95,000 		10,000 -22.9% 9.50 US$95,000
2007-12-20 2007-12-18 S Sale GUTSHALL THOMAS L Non-Executive Director
7,500 -60.0%
9.01
US$67,560 		7,500 -60.0% 9.01 US$67,560
2007-12-12 2007-12-11 PlS Planned sale BLACKBURN BRENT K

SVP, Drug Discovery & Dev

Officer
3,951 -11.5%
9.63
US$38,048 		3,951 -11.5% 9.63 US$38,048
2007-12-12 2007-12-11 PlS Planned sale BLACKBURN BRENT K

SVP, Drug Discovery & Dev

Officer
15,000 -30.4%
9.74
US$146,100 		15,000 -30.4% 9.74 US$146,100
2007-12-11 2007-12-10 PlS Planned sale SPIEGELMAN DANIEL K

SVP, CFO

Officer
8,000 -46.4%
10.03
US$80,240 		8,000 -46.4% 10.03 US$80,240
2007-11-13 2007-11-09 PlS Planned sale STUART LEWIS J

SVP COMMERCIAL OPERATIONS

Officer
2,497 -31.7%
10.19
US$25,444 		2,497 -31.7% 10.19 US$25,444
2007-08-17 2007-08-16 S Sale BLACKBURN BRENT K

SVP, Drug Discovery & Dev

Officer
10,000 -30.2%
10.09
US$100,900 		10,000 -30.2% 10.09 US$100,900
2007-01-18 2007-01-17 PlS Planned sale SPIEGELMAN DANIEL K

SVP, CFO

Officer
7,000 -61.5%
13.93
US$97,510 		7,000 -61.5% 13.93 US$97,510
2006-12-21 2006-12-19 S Sale MCNEIL BARBARA J Non-Executive Director
1,800 -41.9%
13.60
US$24,480 		1,800 -41.9% 13.60 US$24,480
2006-12-13 2006-12-12 PlS Planned sale SPIEGELMAN DANIEL K

SVP, CFO

Officer
3,000 -46.6%
12.92
US$38,760 		3,000 -46.6% 12.92 US$38,760
2006-03-08 2006-03-07 S Sale MCNEIL BARBARA J Non-Executive Director
8,000 -76.2%
24.53
US$196,240 		8,000 -76.2% 24.53 US$196,240
2005-11-04 2005-11-03 S Sale SPIEGELMAN DANIEL K

SVP, CFO

Officer
26,500 -100.0%
25.21
US$668,065 		26,500 -100.0% 25.21 US$668,065
2005-08-31 2005-08-29 S Sale BLACKBURN BRENT K

SVP, Drug Discovery & Dev

Officer
8,000 -44.5%
25.73
US$205,840 		8,000 -44.5% 25.73 US$205,840
2005-08-30 2005-08-26 S Sale SPIEGELMAN DANIEL K

SVP, CFO

Officer
21,506 -100.0%
26.24
US$564,317 		21,506 -100.0% 26.24 US$564,317
2005-03-15 2005-03-14 B Purchase SHENK THOMAS E Non-Executive Director
1,000 +inf%
20.36
US$20,360 		1,000 +inf% 20.36 US$20,360
2004-12-20 2004-12-16 PlS Planned sale SPIEGELMAN DANIEL K

Senior Vice President and CFO

Officer
7,500 -27.3%
23.86
US$178,954 		7,500 -27.3% 23.86 US$178,954
Explore more

More insider trading research around Gilead Palo Alto Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America